Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in cardiomyocytes | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16259
Sealed predictions
- PLCXD3 in dopamine neurons, braak+0.47 (p 0.202) → +0.58 (p 0.103)receipt 16266
Swarm cases
receipt 16266: PLCXD3 in dopamine neurons, braak
- power
- full sample +0.54 (p 0.019, n 18), 95% CI +0.10 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.55 (p 0.018, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.029, n 18). not the mix.
- skeptic
- leave-one-out range +0.48 to +0.64, sign flips 0; without severely affected donors +0.54 (p 0.019, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLCXD3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts